Immunogenicity of the hepatitis A vaccine 20 years after infant immunization
•We evaluated Hepatitis A vaccine immunogenicity 20 years after infant vaccination.•Hepatitis A vaccine seropositivity was identified among 68% of participants.•We predict 50% of participants will no longer be seropositive by 27 years of age.•Studies are needed to determine if protection against Hep...
Gespeichert in:
Veröffentlicht in: | Vaccine 2020-07, Vol.38 (32), p.4940-4943 |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | •We evaluated Hepatitis A vaccine immunogenicity 20 years after infant vaccination.•Hepatitis A vaccine seropositivity was identified among 68% of participants.•We predict 50% of participants will no longer be seropositive by 27 years of age.•Studies are needed to determine if protection against Hepatitis A will also be lost.
To determine the duration of immunity provided by the Hepatitis A vaccination (HepA), we evaluated a cohort of participants in Alaska 20 years after being immunized as infants. At recruitment, participants received two doses of inactivated HepA vaccine on one of three schedules. We conducted hepatitis A antibody (anti-HAV) testing for participants at the 20-year time-point. Seventy-five of the original 183 participants (41%) were available for follow-up. The overall anti-HAV geometric mean concentration was 29.9 mIU/mL (95% CI 22.4 mIU/mL, 39.7 mIU/mL) and 50 participants (68%) remained seropositive (titer ≥ 20 mIU/mL). Using a fractional polynomial model, the predicted percent seropositive at 25 years was 55.3%, 49.8% at 30 years and 45.7% at 35 years, suggesting that the percent sero-positive could drop below 50% earlier than previously expected. Further research is necessary to understand if protection continues after seropositivity diminishes or if a HepA booster dose may become necessary. |
---|---|
ISSN: | 0264-410X 1873-2518 |
DOI: | 10.1016/j.vaccine.2020.05.069 |